Finally, in-depth mechanistic studies exploring metabolic reprogramming, mitochondrial function, and immune microenvironment regulation will be essential to fully elucidate the multidimensional protective actions of SGLT2 inhibition in NAFLD [51]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.